| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
| Breedlove Robert Charles | Principal Accounting Officer | 0 | $0 | 1 | $7,079 | $-7,079 |
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux …
Over the last 12 months, insiders at Phathom Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Phathom Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Phathom Pharmaceuticals, Inc. have bought $295,011 and sold $13.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,780 shares for transaction amount of $14,609 was made by Topper James N (director) on 2025‑05‑21.
| 2025-11-03 | Sale | Breedlove Robert Charles | Principal Accounting Officer | 524 0.0007% | $13.51 | $7,079 | -18.06% | |
| 2025-09-05 | Sale | Breedlove Robert Charles | Principal Accounting Officer | 461 0.0006% | $12.09 | $5,573 | -4.05% | |
| 2025-07-16 | Sale | Breedlove Robert Charles | Principal Accounting Officer | 1,692 0.0024% | $8.36 | $14,152 | +43.82% | |
| 2025-05-21 | Topper James N | director | 3,780 0.0054% | $3.86 | $14,609 | +204.62% | ||
| 2025-05-14 | Topper James N | director | 6,300 0.0092% | $3.32 | $20,919 | +265.54% | ||
| 2025-05-13 | Topper James N | director | 1,120 0.0015% | $3.16 | $3,543 | +258.91% | ||
| 2025-05-12 | Topper James N | director | 12,601 0.0174% | $3.04 | $38,301 | +276.19% | ||
| 2025-05-09 | Topper James N | director | 35,602 0.0523% | $3.22 | $114,616 | +276.75% | ||
| 2025-05-07 | Parikh Asit | director | 5,000 0.0072% | $2.40 | $11,985 | +392.50% | ||
| 2025-05-06 | Parikh Asit | director | 5,000 0.0078% | $2.60 | $13,000 | +392.08% | ||
| 2025-04-07 | Sale | Henderson Molly | CFO and CBO | 3,678 0.0049% | $4.55 | $16,740 | +133.98% | |
| 2025-03-13 | Parikh Asit | director | 10,000 0.015% | $4.42 | $44,200 | +168.48% | ||
| 2025-01-21 | Sale | Curran Terrie | President and Chief Executive | 19,109 0.0281% | $6.59 | $125,884 | +41.09% | |
| 2025-01-21 | Sale | Nabulsi Azmi | Chief Operating Officer | 7,886 0.0116% | $6.59 | $51,957 | +41.09% | |
| 2025-01-21 | Sale | Henderson Molly | CFO and CBO | 6,583 0.0097% | $6.59 | $43,371 | +41.09% | |
| 2024-12-19 | Sale | Nabulsi Azmi | Chief Operating Officer | 1,118 0.0017% | $8.00 | $8,944 | +10.61% | |
| 2024-12-19 | Sale | Henderson Molly | CFO and CBO | 1,291 0.0019% | $8.00 | $10,328 | +10.61% | |
| 2024-12-13 | Parikh Asit | director | 10,000 0.0149% | $8.12 | $81,248 | +8.24% | ||
| 2024-12-13 | KARBE FRANK | director | 12,500 0.0182% | $7.93 | $99,084 | +8.24% | ||
| 2024-07-15 | Sale | Curran Terrie | President and Chief Executive | 33,848 0.0663% | $11.72 | $396,699 | -30.90% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 7284269 8.9607% | $41.81M | 1 | 0 | +47.21% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 3115008 3.8319% | $17.88M | 3 | 1 | +53.57% |
| Edwards Jonathan S. | director | 2019877 2.4847% | $11.59M | 1 | 0 | +47.21% |
| Curran Terrie | President and Chief Executive | 360465 0.4434% | $2.07M | 2 | 7 | +28.42% |
| Nabulsi Azmi | Chief Operating Officer | 233390 0.2871% | $1.34M | 2 | 16 | +23.07% |
| Parikh Asit | director | 95500 0.1175% | $548,170.00 | 11 | 0 | +108.01% |
| Henderson Molly | CFO and CBO | 89868 0.1106% | $515,842.32 | 1 | 13 | |
| Topper James N | director | 59403 0.0731% | $340,973.22 | 5 | 0 | +256.4% |
| KARBE FRANK | director | 57000 0.0701% | $327,180.00 | 1 | 0 | +8.24% |
| COLA MICHAEL F | director | 9798 0.0121% | $56,240.52 | 1 | 0 | +47.21% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$8,866,498 | 28 | 33.64% | $474.26M |
| Increased Positions | 99 | +69.23% | 6M | +9.05% |
| Decreased Positions | 60 | -41.96% | 6M | -9.67% |
| New Positions | 48 | New | 3M | New |
| Sold Out Positions | 10 | Sold Out | 825,537 | Sold Out |
| Total Postitions | 182 | +27.27% | 62M | -0.61% |
| Frazier Life Sciences Management, L.P. | $195,849.00 | 17.56% | 12.47M | 0 | 0% | 2025-09-30 |
| Medicxi Ventures Management (Jersey) Ltd | $117,268.00 | 10.51% | 7.46M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $79,830.00 | 7.16% | 5.08M | +3M | +125.79% | 2025-09-30 |
| Invesco Ltd. | $60,719.00 | 5.44% | 3.86M | -275,101 | -6.64% | 2025-09-30 |
| Carlyle Group Inc. | $54,935.00 | 4.93% | 3.5M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $53,451.00 | 4.79% | 3.4M | +86,976 | +2.62% | 2025-09-30 |
| Vanguard Group Inc | $50,517.00 | 4.53% | 3.22M | +428,261 | +15.37% | 2025-09-30 |
| Ensign Peak Advisors, Inc | $39,328.00 | 3.53% | 2.5M | -16,628 | -0.66% | 2025-09-30 |
| Nea Management Company, Llc | $30,794.00 | 2.76% | 1.96M | 0 | 0% | 2025-09-30 |
| 683 Capital Management, Llc | $28,598.00 | 2.56% | 1.82M | -284,620 | -13.52% | 2025-09-30 |